JP2006505566A - 胃酸分泌阻害組成物 - Google Patents

胃酸分泌阻害組成物 Download PDF

Info

Publication number
JP2006505566A
JP2006505566A JP2004545135A JP2004545135A JP2006505566A JP 2006505566 A JP2006505566 A JP 2006505566A JP 2004545135 A JP2004545135 A JP 2004545135A JP 2004545135 A JP2004545135 A JP 2004545135A JP 2006505566 A JP2006505566 A JP 2006505566A
Authority
JP
Japan
Prior art keywords
dosage form
acid
salt
proton pump
pump inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004545135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505566A5 (enExample
Inventor
アンデルス・ペッターソン
クリステル・ニストレーム
イヴォンヌ・ホーカンソン
Original Assignee
オレクソ・アクチエボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレクソ・アクチエボラゲット filed Critical オレクソ・アクチエボラゲット
Publication of JP2006505566A publication Critical patent/JP2006505566A/ja
Publication of JP2006505566A5 publication Critical patent/JP2006505566A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004545135A 2002-10-16 2003-10-15 胃酸分泌阻害組成物 Ceased JP2006505566A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203065A SE0203065D0 (sv) 2002-10-16 2002-10-16 Gastric acid secretion inhibiting composition
PCT/SE2003/001598 WO2004035090A1 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010288271A Division JP2011057714A (ja) 2002-10-16 2010-12-24 胃酸分泌阻害組成物

Publications (2)

Publication Number Publication Date
JP2006505566A true JP2006505566A (ja) 2006-02-16
JP2006505566A5 JP2006505566A5 (enExample) 2006-10-05

Family

ID=20289290

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004545135A Ceased JP2006505566A (ja) 2002-10-16 2003-10-15 胃酸分泌阻害組成物
JP2010288271A Pending JP2011057714A (ja) 2002-10-16 2010-12-24 胃酸分泌阻害組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010288271A Pending JP2011057714A (ja) 2002-10-16 2010-12-24 胃酸分泌阻害組成物

Country Status (14)

Country Link
US (5) US7785626B2 (enExample)
EP (2) EP1558288A1 (enExample)
JP (2) JP2006505566A (enExample)
KR (1) KR101139862B1 (enExample)
CN (1) CN1726048B (enExample)
AU (1) AU2003267924C1 (enExample)
CA (1) CA2501201C (enExample)
MX (1) MXPA05004118A (enExample)
NO (1) NO20052019L (enExample)
NZ (1) NZ539262A (enExample)
PL (1) PL376178A1 (enExample)
RU (1) RU2340358C2 (enExample)
SE (1) SE0203065D0 (enExample)
WO (1) WO2004035090A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528198A (ja) * 2003-07-23 2006-12-14 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ 酸不安定な医薬組成物の即時放出製剤
JP2008105980A (ja) * 2006-10-24 2008-05-08 Zeria Pharmaceut Co Ltd ニザチジン含有医薬組成物
WO2011030659A1 (ja) * 2009-09-08 2011-03-17 協和化学工業株式会社 制酸・緩下用錠剤
JP2012518656A (ja) * 2009-02-23 2012-08-16 アプタリス ファーマテック インコーポレイテッド 抗コリン薬を具える放出制御組成物
KR20150069205A (ko) * 2013-12-13 2015-06-23 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
JP2021507926A (ja) * 2018-01-29 2021-02-25 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む薬剤学的製剤
US11813285B2 (en) 2018-01-29 2023-11-14 Chong Kun Dang Pharmaceutical Corp. Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
EP1875911A4 (en) * 2005-04-28 2010-03-03 Eisai R&D Man Co Ltd STABILIZED COMPOSITION
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
CN101257892B (zh) 2005-05-18 2013-01-02 达沃尔泰拉公司 吸附剂的结肠递送
ES2620293T3 (es) * 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
SI1931346T1 (sl) * 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
EP1967184A4 (en) * 2005-12-28 2011-02-16 Takeda Pharmaceutical SOLID PREPARATION WITH CONTROLLED RELEASE
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
WO2009145905A1 (en) * 2008-05-30 2009-12-03 Pozen Inc. Dosage forms for the rapid and sustained elevation of gastric ph
US20110142905A1 (en) * 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) * 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA2984801A1 (en) * 2015-05-29 2016-12-08 Johnson & Johnson Consumer Inc. Use of organic citrus extract with high antimicrobial capacity as a preservative system in liquids, emulsions, suspensions, creams and antacids
CN105796532B (zh) * 2016-03-28 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种雷贝拉唑钠缓释胶囊及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN105944104B (zh) * 2016-06-17 2018-12-14 上海凯宝药业股份有限公司 一种治疗消化道溃疡的药物组合物
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL SUBSTANCES
CN112020350A (zh) 2018-04-27 2020-12-01 强生消费者公司 液体口服药物剂型
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063280A (ja) * 1998-06-11 2000-02-29 Takeda Chem Ind Ltd 抗ヘリコバクタ―・ピロリ活性胃腸薬

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
DE3400014A1 (de) 1984-01-02 1985-07-18 Henkel KGaA, 4000 Düsseldorf Entschaeumer fuer waessrige dispersionen und loesungen von kunstharzen
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
WO1991019712A1 (en) 1990-06-20 1991-12-26 Aktiebolaget Astra Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
US5244670A (en) 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
CA2125579C (en) 1991-12-17 2005-06-21 Richard C. Fuisz Ulcer prevention treatment composition and method
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
WO1995017080A1 (en) 1993-12-14 1995-06-22 Neo-Concepts, Inc. Solid state power supply circuit for cold cathode lighting
US5407687A (en) 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
WO1997011750A1 (en) * 1995-09-27 1997-04-03 United Defense, L.P. Integrated protective action system
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
DE19709897A1 (de) 1997-03-11 1998-09-17 Hoechst Ag Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
DE69803291T2 (de) * 1997-07-22 2002-08-08 Merck & Co Inc Methoden zur verhinderung von knochenresorption
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US7041313B1 (en) 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
ES2194515T3 (es) 1998-10-06 2003-11-16 Mars Uk Ltd Estereotipia en animales.
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6316469B1 (en) 2000-03-01 2001-11-13 Duke University Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease
US6614262B2 (en) * 2000-11-15 2003-09-02 Texas Instruments Incorporated Failsafe interface circuit with extended drain devices
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063280A (ja) * 1998-06-11 2000-02-29 Takeda Chem Ind Ltd 抗ヘリコバクタ―・ピロリ活性胃腸薬

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528198A (ja) * 2003-07-23 2006-12-14 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ 酸不安定な医薬組成物の即時放出製剤
JP2008105980A (ja) * 2006-10-24 2008-05-08 Zeria Pharmaceut Co Ltd ニザチジン含有医薬組成物
JP2015155441A (ja) * 2009-02-23 2015-08-27 アプタリス ファーマテック インコーポレイテッド 抗コリン薬を具える放出制御組成物
JP2012518656A (ja) * 2009-02-23 2012-08-16 アプタリス ファーマテック インコーポレイテッド 抗コリン薬を具える放出制御組成物
JPWO2011030659A1 (ja) * 2009-09-08 2013-02-07 協和化学工業株式会社 制酸・緩下用錠剤
WO2011030659A1 (ja) * 2009-09-08 2011-03-17 協和化学工業株式会社 制酸・緩下用錠剤
KR20150069205A (ko) * 2013-12-13 2015-06-23 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
JP2021507926A (ja) * 2018-01-29 2021-02-25 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む薬剤学的製剤
JP7009634B2 (ja) 2018-01-29 2022-01-25 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む薬剤学的製剤
US11759428B2 (en) 2018-01-29 2023-09-19 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
US11813285B2 (en) 2018-01-29 2023-11-14 Chong Kun Dang Pharmaceutical Corp. Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate

Also Published As

Publication number Publication date
JP2011057714A (ja) 2011-03-24
US7771747B2 (en) 2010-08-10
AU2003267924B2 (en) 2008-12-11
EP1558288A1 (en) 2005-08-03
NO20052019L (no) 2005-06-15
SE0203065D0 (sv) 2002-10-16
EP2258341A3 (en) 2012-08-29
NO20052019D0 (no) 2005-04-26
US20100151013A1 (en) 2010-06-17
MXPA05004118A (es) 2005-10-05
KR20050083770A (ko) 2005-08-26
AU2003267924C1 (en) 2012-09-20
CN1726048B (zh) 2012-05-30
KR101139862B1 (ko) 2012-07-03
US20060115530A1 (en) 2006-06-01
US20130017263A1 (en) 2013-01-17
CA2501201C (en) 2013-01-08
NZ539262A (en) 2008-04-30
EP2258341A2 (en) 2010-12-08
US20120121664A1 (en) 2012-05-17
PL376178A1 (en) 2005-12-27
CN1726048A (zh) 2006-01-25
CA2501201A1 (en) 2004-04-29
RU2340358C2 (ru) 2008-12-10
US7785626B2 (en) 2010-08-31
RU2005114612A (ru) 2005-10-10
WO2004035090A1 (en) 2004-04-29
AU2003267924A1 (en) 2004-05-04
US20070031497A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
CN1726048B (zh) 抑制胃酸分泌的组合物
US7815940B2 (en) Gastric acid secretion inhibiting composition
EP1411900B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
AU2002253768A1 (en) Gastric acid secretion inhibiting composition
JP2004508396A (ja) 非ステロイド性抗炎症薬およびプロトンポンプ阻害薬を含有する医薬製剤
KR102334699B1 (ko) 프로톤펌프억제제 및 모사프리드를 포함하는 유핵정 제제
WO2005065664A1 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
WO2011144994A1 (en) Pharmaceutical compositions of nsaid and acid inhibitor
EP2364145A1 (en) Dosage forms for the rapid and sustained elevation of gastric ph
HK1148674A (en) Gastric acid secretion inhibiting composition
CN101143143A (zh) 一种治疗胃食管反流疾病与功能性消化不良的药物
HK1095277A (en) Gastric acid secretion inhibiting composition
HK1148936A (en) Gastric acid secretion inhibiting composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110324

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120329

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120406

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140421